2. Search Result
Search Result
Results for "

glycemic

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

1

Biochemical Assay Reagents

6

Peptides

2

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15408A
    Trelagliptin succinate

    SYR-472 succinate

    		 Dipeptidyl Peptidase Metabolic Disease
    Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .
    Trelagliptin succinate
  • HY-P3463
    Beinaglutide

    GLP-1 (human)

    		 GCGR Metabolic Disease Inflammation/Immunology
    Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .
    Beinaglutide
  • HY-113075
    1,5-Anhydrosorbitol

    		Endogenous Metabolite Metabolic Disease
    1,5-Anhydrosorbitol is a short-term marker for glycemic control.
    1,5-Anhydrosorbitol
  • HY-105074
    Farglitazar

    GI262570; GI262570X

    		 PPAR Metabolic Disease
    Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.
    Farglitazar
  • HY-15408
    Trelagliptin

    SYR-472

    		 Dipeptidyl Peptidase Metabolic Disease
    Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .
    Trelagliptin
  • HY-15408AR
    Trelagliptin succinate (Standard)

    		Dipeptidyl Peptidase Metabolic Disease
    Trelagliptin (succinate) (Standard) is the analytical standard of Trelagliptin (succinate). This product is intended for research and analytical applications. Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .
    Trelagliptin succinate (Standard)
  • HY-164870
    FFAR1/FFAR4 agonist-1

    		Free Fatty Acid Receptor Metabolic Disease Inflammation/Immunology
    FFAR1/FFAR4 agonist-1 (compound 83) is a FFAR1/FFAR4 agonist with the EC50 of 1 nM A and 4nM for FFAR1 and FFAR4, respectively. FFAR1/FFAR4 agonist-1 can be used for study of glycemic control .
    FFAR1/FFAR4 agonist-1
  • HY-16421
    Ragaglitazar

    (-)-DRF 2725; NNC 61-0029

    		 PPAR Metabolic Disease
    Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.
    Ragaglitazar
  • HY-113075S
    1,5-Anhydrosorbitol-13C

    		Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    1,5-Anhydrosorbitol- 13C is the 13C labeled 1,5-Anhydrosorbitol. 1,5-Anhydrosorbitol is a short-term marker for glycemic cont[1][2].
    1,5-Anhydrosorbitol-13C
  • HY-N9911
    1,5-Anhydro-D-mannitol

    		Others Metabolic Disease
    1,5-Anhydro-D-mannitol is the analogue of 1,5-Anhydrosorbitol (HY-113075), and can be used as an experimental control. 1,5-Anhydrosorbitol is a short-term marker for glycemic control.
    1,5-Anhydro-D-mannitol
  • HY-112668B
    Retagliptin hydrochloride

    SP2086 hydrochloride

    		 Others Others
    Retagliptin (SP2086) hydrochloride is a potent inhibitor of beta-amino acids and dipeptidyl peptidase-4 (DPP-4). Retagliptin (SP2086) hydrochloride inhibits type 2 diabetes and improves glycemic control by prolonging the action of intestinal hormones such as glucagon-like peptide-1 (GLP-1) .
    Retagliptin hydrochloride
  • HY-162513
    DPP-4-IN-10

    		Dipeptidyl Peptidase Cardiovascular Disease
    DPP-4-IN-10 (compound 1) is a DPP-4 inhibitor. DPP-4-IN-10 is orally active. DPP-4-IN-10 blocks the degradation of GLP-1 and GIP, which may improve glycemic control in type 2 diabetes (T2MD) .
    DPP-4-IN-10
  • HY-15408S
    Trelagliptin-13C,d3

    SYR-472-13C,d3

    		 Isotope-Labeled Compounds Dipeptidyl Peptidase Metabolic Disease
    Trelagliptin-13C,d3 is a deuterated labeled Trelagliptin . Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .
    Trelagliptin-13C,d3
  • HY-125156
    Dapagliflozin-3-O-β-D-glucuronide

    BMS-801576

    		 Endogenous Metabolite Metabolic Disease
    Dapagliflozin-3-O-β-D-glucuronide (BMS-801576) is the metabolite of Dapagliflozin (HY-10450), and is formed in the liver and kidney by uridine diphosphate glucuronosyltransferase-1A9 (UGT1A9). Dapagliflozin is a selective inhibitor for SGLT2, that can be used to improve glycemic control and attenuate type 2 diabetes .
    Dapagliflozin-3-O-β-D-glucuronide
  • HY-P10341
    ZP3022

    		GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
    ZP3022
  • HY-P10318
    SHR-2042

    		GLP Receptor Endocrinology
    SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
    SHR-2042
  • HY-P3101
    GLP-1(28-36)amide

    		GCGR Cardiovascular Disease Metabolic Disease
    GLP-1(28-36)amide, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide has anti-diabetic and cardioprotection effects .
    GLP-1(28-36)amide
  • HY-P3101A
    GLP-1(28-36)amide TFA

    		GCGR Cardiovascular Disease Metabolic Disease
    GLP-1(28-36)amide TFA, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide TFA is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide TFA has anti-diabetic and cardioprotection effects .
    GLP-1(28-36)amide TFA
  • HY-100546
    GSK-LSD1

    		Histone Demethylase Infection Metabolic Disease Cancer
    GSK-LSD1 is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis .
    GSK-LSD1
  • HY-125088
    Oleoylestrone

    		Others Others
    Oleoyl-estrone (OE) is a signaling molecule derived from adipose tissue that reduces energy intake and body fat while maintaining energy expenditure and blood glucose balance. In studies in adrenalodepleted female rats, administration of OE resulted in significant fat mobilization, reduced food intake, and sustained energy expenditure. However, concomitant administration of corticosterone inhibits OE-induced fat mobilization and aggravates insulin resistance and glycemic imbalance by promoting fat deposition. This suggests that corticosterone has an antagonistic effect on the beneficial metabolic effects of OE, particularly on lipid metabolism and insulin sensitivity .
    Oleoylestrone
  • HY-113058
    3-Hydroxyoctanoic acid

    		Biochemical Assay Reagents Others
    3-Hydroxyoctanoic acid is a hydroxylated fatty acid that has been found in the LPS of Pseudomonas aeruginosa and in methyl-branched poly(3-hydroxyalkanoate) (PHA) polymers produced by Pseudomonas oleophores. It is an agonist of the orphan receptor GPR109B, increasing intracellular calcium in human neutrophils endogenously expressing GPR109B. 3-Hydroxycaprylic acid prevents lipolysis in human adipocytes and is upregulated in human plasma in response to a ketogenic diet. Plasma levels of 3-hydroxyoctanoic acid were also increased 3.41-fold in human male runners exhausted on a treadmill and in a mouse model of autism spectrum disorder (ASD) fed a high-glycemic diet.
    3-Hydroxyoctanoic acid

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: